These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 31367835)

  • 21. Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody.
    Akce M; Liu Y; Zakka K; Martini DJ; Draper A; Alese OB; Shaib WL; Wu C; Wedd JP; Sellers MT; Bilen MA; El-Rayes BF
    Am J Clin Oncol; 2021 Feb; 44(2):74-81. PubMed ID: 33350681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone.
    Boegemann M; Schlack K; Thomes S; Steinestel J; Rahbar K; Semjonow A; Schrader AJ; Aringer M; Krabbe LM
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy.
    Bartlett EK; Flynn JR; Panageas KS; Ferraro RA; Sta Cruz JM; Postow MA; Coit DG; Ariyan CE
    Cancer; 2020 Jan; 126(1):76-85. PubMed ID: 31584709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baseline neutrophil-lymphocyte ratio (≥2.8) as a prognostic factor for patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation.
    Shen L; Zhang H; Liang L; Li G; Fan M; Wu Y; Zhu J; Zhang Z
    Radiat Oncol; 2014 Dec; 9():295. PubMed ID: 25518933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inflammatory markers and overall survival in older adults with cancer.
    Nishijima TF; Deal AM; Lund JL; Nyrop KA; Muss HB; Sanoff HK
    J Geriatr Oncol; 2019 Mar; 10(2):279-284. PubMed ID: 30131235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Baseline and early changes in the neutrophil-lymphocyte ratio (NLR) predict survival outcomes in advanced colorectal cancer patients treated with immunotherapy.
    Ouyang H; Xiao B; Huang Y; Wang Z
    Int Immunopharmacol; 2023 Oct; 123():110703. PubMed ID: 37536184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
    Bagley SJ; Kothari S; Aggarwal C; Bauml JM; Alley EW; Evans TL; Kosteva JA; Ciunci CA; Gabriel PE; Thompson JC; Stonehouse-Lee S; Sherry VE; Gilbert E; Eaby-Sandy B; Mutale F; DiLullo G; Cohen RB; Vachani A; Langer CJ
    Lung Cancer; 2017 Apr; 106():1-7. PubMed ID: 28285682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer.
    Derman BA; Macklis JN; Azeem MS; Sayidine S; Basu S; Batus M; Esmail F; Borgia JA; Bonomi P; Fidler MJ
    BMC Cancer; 2017 Feb; 17(1):141. PubMed ID: 28209123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lymphocytes and Neutrophil-to-Lymphocyte Ratio Variations After Selective Internal Radiation Treatment for HCC: A Retrospective Cohort Study.
    Estrade F; Lescure C; Muzellec L; Pedrono M; Palard X; Pracht M; Le Sourd S; Rolland Y; Uguen T; Garin E; Edeline J
    Cardiovasc Intervent Radiol; 2020 Aug; 43(8):1175-1181. PubMed ID: 32342156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neutrophil-lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival.
    Mason M; Maurice C; McNamara MG; Tieu MT; Lwin Z; Millar BA; Menard C; Laperriere N; Milosevic M; Atenafu EG; Mason W; Chung C
    J Neurooncol; 2017 May; 132(3):463-471. PubMed ID: 28332000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased Neutrophil-Lymphocyte Ratio Is a Poor Prognostic Factor in Patients with Esophageal Cancer in a High Incidence Area in China.
    Yutong H; Xiaoli X; Shumei L; Shan S; Di L; Baoen S
    Arch Med Res; 2015 Oct; 46(7):557-63. PubMed ID: 26385485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma.
    Lalani AA; Xie W; Martini DJ; Steinharter JA; Norton CK; Krajewski KM; Duquette A; Bossé D; Bellmunt J; Van Allen EM; McGregor BA; Creighton CJ; Harshman LC; Choueiri TK
    J Immunother Cancer; 2018 Jan; 6(1):5. PubMed ID: 29353553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The prognostic impact of neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR) in patients with distal bile duct cancer.
    Miyahara Y; Takashi S; Shimizu Y; Ohtsuka M
    World J Surg Oncol; 2020 Apr; 18(1):78. PubMed ID: 32321522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs).
    Li Y; Zhang Z; Hu Y; Yan X; Song Q; Wang G; Chen R; Jiao S; Wang J
    Front Oncol; 2020; 10():654. PubMed ID: 32656072
    [No Abstract]   [Full Text] [Related]  

  • 35. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?
    Ulas A; Avci N; Kos T; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
    J BUON; 2015; 20(3):714-22. PubMed ID: 26214622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma.
    Pointer DT; Roife D; Powers BD; Murimwa G; Elessawy S; Thompson ZJ; Schell MJ; Hodul PJ; Pimiento JM; Fleming JB; Malafa MP
    BMC Cancer; 2020 Aug; 20(1):750. PubMed ID: 32782024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis.
    Sacdalan DB; Lucero JA; Sacdalan DL
    Onco Targets Ther; 2018; 11():955-965. PubMed ID: 29503570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy.
    Templeton AJ; Knox JJ; Lin X; Simantov R; Xie W; Lawrence N; Broom R; Fay AP; Rini B; Donskov F; Bjarnason GA; Smoragiewicz M; Kollmannsberger C; Kanesvaran R; Alimohamed N; Hermanns T; Wells JC; Amir E; Choueiri TK; Heng DY
    Eur Urol; 2016 Aug; 70(2):358-64. PubMed ID: 26924770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Chen X; Meng F; Jiang R
    Front Oncol; 2021; 11():746976. PubMed ID: 34900692
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel.
    Buttigliero C; Pisano C; Tucci M; Vignani F; Bertaglia V; Iaconis D; Guglielmini P; Numico G; Scagliotti GV; Di Maio M
    Acta Oncol; 2017 Apr; 56(4):555-562. PubMed ID: 28068151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.